Morning for Irofulven, What Could be fiNER?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33472911.
- Also identified by DOI 10.1158/1078-0432.CCR-20-4708 and PMC identifier 8026716.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancers with DNA repair dysfunction are vulnerable to DNA-damaging agents that invoke a requirement for the disabled repair mechanism. Genome sequencing, coupled with a detailed understanding of mechanisms of DNA repair, has accelerated the discovery of pathway-selective agents that target DNA repair deficiencies in a tumor tissue agnostic manner.<i>See related articles by Topka et al., p. 1997 and Börcsök et al., p. 2011</i>.
Medical subject headings
- Antineoplastic Agents, Alkylating
- DNA Repair
- Sesquiterpenes